Advertisement
Canada markets close in 4 hours 10 minutes

  • S&P/TSX

    21,933.99
    +48.61 (+0.22%)
     

  • S&P 500

    5,104.29
    +55.87 (+1.11%)
     

  • DOW

    38,244.94
    +159.14 (+0.42%)
     

  • CAD/USD

    0.7310
    -0.0013 (-0.18%)
     

  • CRUDE OIL

    83.86
    +0.29 (+0.35%)
     

  • Bitcoin CAD

    86,878.72
    -444.72 (-0.51%)
     

  • CMC Crypto 200

    1,320.62
    -75.92 (-5.43%)
     

  • GOLD FUTURES

    2,346.70
    +4.20 (+0.18%)
     

  • RUSSELL 2000

    1,994.18
    +13.06 (+0.66%)
     

  • 10-Yr Bond

    4.6670
    -0.0390 (-0.83%)
     

  • NASDAQ

    15,944.51
    +332.75 (+2.13%)
     

  • VOLATILITY

    15.47
    +0.10 (+0.65%)
     

  • FTSE

    8,145.21
    +66.35 (+0.82%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6836
    +0.0015 (+0.22%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

Got $4,000? 4 Game-Changing Stocks to Buy in 2021

Sean Williams, The Motley Fool
·6 min read
Got $4,000? 4 Game-Changing Stocks to Buy in 2021

Few companies in the drug-development space have offered game-changing potential for their patients quite like Vertex Pharmaceuticals (NASDAQ: VRTX). While all eyes are on COVID-19 vaccine stocks, Vertex is simply dominating the treatment landscape for cystic fibrosis (CF) -- a genetic disease characterized by thick mucus production that can obscure the lungs and pancreas. Although CF doesn't have a cure, Vertex has brought to market a number of gene-based treatments that are improving lung function and quality of life for CF patients.

Continue reading